Back to Search
Start Over
Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis.
- Source :
-
Dermatologic clinics [Dermatol Clin] 2024 Jul; Vol. 42 (3), pp. 417-428. Date of Electronic Publication: 2024 Feb 26. - Publication Year :
- 2024
-
Abstract
- National guidelines define psoriasis as a risk enhancer for cardiovascular disease and recommend increased monitoring and more intense management of cardiovascular risk factors in these patients, who face an increased burden of cardiovascular disease morbidity and mortality. Screening for modifiable cardiovascular risk factors, including blood pressure, weight, cholesterol, glucose, and smoking, can be efficiently incorporated into routine dermatology clinical practice. Partnerships with primary care providers and preventive cardiologists are essential to improving management of cardiovascular risk in patients with psoriasis.<br />Competing Interests: Disclosure J.M. Gelfand served as a consultant for Abbvie, Artax (DSMB), BMS, Boehringer Ingelheim, Celldex (DSMB), FIDE (which is sponsored by multiple pharmaceutical companies) GSK, Inmagene (DSMB), Twill, Lilly (DMC), Leo, Moonlake (DSMB), Janssen Biologics, Novartis Corp, UCB (DSMB), Neuroderm (DSMB), and Veolia North America receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from Amgen, United States, BMS, United States, and Pfizer Inc., United States; received payment for continuing medical education work related to psoriasis that was supported indirectly by pharmaceutical sponsors; is a co-patent holder of resiquimod for the treatment of cutaneous T-cell lymphoma; is a Deputy Editor for the Journal of Investigative Dermatology receiving honoraria from the Society for Investigative Dermatology; is the Chief Medical Editor for Healio Dermatology (receiving honoraria); and is a member of the Board of Directors for the International Psoriasis Council and the Medical Dermatology Society, receiving no honoraria. D.E. Soffer has served as consultant for Akcea, Amgen, Amryt, Ionis, Novartis, and Partnership for Health Analytics Research; was an investigator for Akcea, Amgen, Amryt, Ionis, Novartis, Regeneron, and Verve Therapeutics; and did data monitoring for Amgen.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1558-0520
- Volume :
- 42
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Dermatologic clinics
- Publication Type :
- Academic Journal
- Accession number :
- 38796273
- Full Text :
- https://doi.org/10.1016/j.det.2024.02.008